Form 4: VolitionRx Executive Receives Stock Units in Lieu of Cash Compensation

Jacob Vincent Micallef, Chief Scientific Officer of VolitionRx Ltd, received 47,837 restricted stock units (RSUs) in lieu of cash compensation on September 1, 2024.

Summary

• On September 1, 2024, Jacob Vincent Micallef, the Chief Scientific Officer of VolitionRx Ltd, was granted 47,837 restricted stock units (RSUs) under the company's 2015 Stock Incentive Plan.
• These RSUs were awarded in place of cash compensation.
• The RSUs vest in three installments of 15,946 units, 15,946 units, and 15,945 units on September 1, 2024, October 1, 2024 and November 1, 2024, respectively, are also subject to further time-based vesting in a single installment on June 1, 2025, contingent upon continued service.
• Upon vesting, Micallef will receive shares of common stock equal to the number of vested RSUs.
• Micallef also indirectly owns 55,000 shares of common stock through his spouse and 38,113 shares through Borlaug Limited, where he is a controlling director.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of RSUs is a standard practice and indicates confidence in the company's future, but it's not a major event.

Positives

• The grant of RSUs aligns Micallef's interests with those of the shareholders, incentivizing him to contribute to the company's long-term success.
• Using RSUs instead of cash may preserve the company's cash reserves.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the RSUs.

Industry Context

The use of RSUs as compensation is a common practice in the biotechnology industry to attract and retain talent while conserving cash.

Comparison to Industry Standards

• Many biotech companies, such as Exact Sciences and Guardant Health, use stock options and RSUs as part of their compensation packages for executives.
• The vesting schedule and terms of the RSUs are generally in line with industry standards for executive compensation.

Stakeholder Impact

• Shareholders may view the RSU grant positively as it aligns management's interests with theirs.
• Employees may see it as a positive sign of the company's commitment to its leadership.

Key Dates